Multiple Myeloma Clinical Trial

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Summary

The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limiting toxicities (DLTs). Participants will be given a 3 day course of conditioning chemotherapy followed by a single infusion of KITE-585.

View Full Description

Full Description

Participants with relapsed/refractory multiple myeloma can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, ECG and echocardiogram of the heart, brain MRI, and blood draws. Eligible participants have white blood cells collected by leukapheresis. These cells are genetically modified to make the experimental treatment KITE-585. Participants receive conditioning chemotherapy prior to the KITE-585 infusion. After the KITE-585 infusion, participants will be followed for side effects and effect of KITE-585 on their myeloma. Study procedures may be performed while hospitalized and/or in the outpatient setting. Subjects who received an infusion of KITE-585 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Measurable relapsed or refractory myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

Absolute neutrophil count (ANC) ≥ 1,000/µL
Platelet count ≥ 75,000/µL
Absolute lymphocyte count ≥ 100/µL
Creatinine clearance above limits set in the protocol for each cohort
Normal cardiac function as assessed by electrocardiogram (ECG) and echocardiogram
Baseline oxygen saturation > 92% on room air and no clinically significant pleural effusion

Key Exclusion Criteria:

Plasma cell leukemia
Non-secretory multiple myeloma
History of Central nervous system (CNS) involvement by multiple myeloma
Prior CAR therapy or other genetically modified T cells
Inadequate washout from prior therapy
Autologous stem cell transplant within 6 weeks before enrollment or any history of allogenic transplant
History of active autoimmune disease
History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within 6 months before enrollment
Recent history of other (non multiple myeloma) cancer
Active viral, fungal, bacterial or other infection

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

17

Study ID:

NCT03318861

Recruitment Status:

Terminated

Sponsor:

Kite, A Gilead Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

David Geffen School of Medicine at UCLA
Los Angeles California, 90095, United States
H. Lee Moffitt Cancer Center
Tampa Florida, 33612, United States
Winship Cancer Institute, Emory University
Atlanta Georgia, 30322, United States
University of Chicago Medical Center
Chicago Illinois, 60637, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02114, United States
Mayo Clinic
Rochester Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

17

Study ID:

NCT03318861

Recruitment Status:

Terminated

Sponsor:


Kite, A Gilead Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.